CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 449 enrolled
Drug / intervention
E10030 plus Lucentis +1 moredrug
Likely dose
Lucentis 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01089517
NCT01089517Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration

Ophthotech Corporation·interventional·Posted Mar 18, 2010·Updated Mar 19, 2024

In Brief

A Phase 2 clinical trial evaluating E10030 plus Lucentis and Lucentis for Age-Related Macular Degeneration. Completed, enrolled 449 participants across 1 site.

Detailed Summary

The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Macular Degeneration
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 18, 2010
Enrollment StartMar 1, 2010
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.3 years ago

Interventions

E10030 plus Lucentisdrug

once a month intravitreal injection

Lucentisdrug

10 mg/mL intravitreal injection monthly